Molecular PET imaging in multicenter Alzheimer’s therapeutic trials: current trends and implementation strategies

References

• Marek K, Jennings D, Tamagnan G, Seibyl J. Biomarkers for Parkinson’s disease: tools to assess Parkinson’s disease onset and progression. Ann. Neurol.64(Suppl. 2), S111–S121 (2008).
   PubMed Web of Science ®Google Scholar
• Walhovd KB, Fjell AM, Brewer J et al. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR Am. J. Neuroradiol.31(2), 347–354 (2010).
   PubMed Web of Science ®Google Scholar
• Ravina B, Tanner C, Dieuliis D et al. A longitudinal program for biomarker development in Parkinson’s disease: a feasibility study. Mov. Disord.24(14), 2081–2090 (2009).
   PubMed Web of Science ®Google Scholar
• Sojkova J, Resnick SM. In vivo human amyloid imaging. Curr. Alzheimer Res.8(4), 366–372 (2011).
   PubMedGoogle Scholar
• Nelissen N, Van Laere K, Thurfjell L et al. Phase I study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J. Nucl. Med.50(8), 1251–1259 (2009).
   PubMed Web of Science ®Google Scholar
• Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, de Leon MJ. Pre-clinical detection of Alzheimer’s disease using FDG-PET, with or without amyloid imaging. J. Alzheimers Dis.20(3), 843–854 (2010).
   PubMed Web of Science ®Google Scholar
• Rowe CC, Ackerman U, Browne W et al. Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol.7(2), 129–135 (2008).
   PubMed Web of Science ®Google Scholar
• Wong DF, Rosenberg PB, Zhou Y et al.In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J. Nucl. Med.51(6), 913–920 (2010).
   PubMed Web of Science ®Google Scholar
• Vandenberghe R, Van Laere K, Ivanoiu A et al.18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a Phase 2 trial. Ann. Neurol.68(3), 319–329 (2010).
   PubMed Web of Science ®Google Scholar
• Hampel H, Frank R, Broich K et al. Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives. Nat. Rev. Drug Dis.9(7), 560–574 (2010).
   PubMed Web of Science ®Google Scholar
• Joshi A, Koeppe RA, Fessler JA. Reducing between scanner differences in multi-center PET studies. Neuroimage46(1), 154–159 (2009).
   PubMedGoogle Scholar
• Jack CR Jr, Bernstein MA, Fox NC et al. The Alzheimer’s Disease Neuroimaging Initiative (ADNI): MRI methods. J. Magn. Reson. Imaging27(4), 685–691 (2008).
   PubMed Web of Science ®Google Scholar
• Alzheimer ’s Disease Neuroimaging Initiative (ADNI). PET Technical Procedures Version 9.5. ADNI, CA, USA, 1–60 (2006).
   Google Scholar
• Seibyl J, Marek K, Zubal IG. The role of the core imaging laboratory in multicenter trials. Semin. Nucl. Med.40(5), 338–346 (2010).
   PubMedGoogle Scholar
• Thomas BA, Erlandsson K, Modat M et al. The importance of appropriate partial volume correction for PET quantification in Alzheimer’s disease. Eur. J. Nucl. Med. Mol. Imaging38(6), 1104–1119 (2011).
   PubMed Web of Science ®Google Scholar
• Tzourio-Mazoyer N, Landeau B, Papathanassiou D et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage15, 273–289 (2002).
   PubMed Web of Science ®Google Scholar
• Haense C, Herholz K, Jagust WJ, Heiss WD. Performance of FDG PET for detection of Alzheimer’s disease in two independent multicentre samples (NEST-DD and ADNI). Dement. Geriatr. Cogn. Disord.28(3), 259–266 (2009).
   PubMed Web of Science ®Google Scholar
• Landau SM, Harvey D, Madison CM et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol. Aging32(7), 1207–1218 (2011).
   PubMed Web of Science ®Google Scholar
• Senjem ML, Gunter JL, Shiung MM, Petersen RC, Jack CR Jr. Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease. Neuroimage26(2), 600–608 (2005).
   PubMedGoogle Scholar
• Mormino EC, Kluth JT, Madison CM et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain132(Pt 5), 1310–1323 (2009).
   PubMed Web of Science ®Google Scholar
• Jack CR Jr, Vemuri P, Wiste HJ et al. Evidence for ordering of Alzheimer disease biomarkers. Arch. Neurol. doi:20111831-10 (2011) (Epub ahead of print).
   Google Scholar
• Morris JC, Roe CM, Grant EA et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch. Neurol.66(12), 1469–1475 (2009).
   PubMed Web of Science ®Google Scholar
• Engler H, Forsberg A, Almkvist O et al. Two year follow up of amyloid deposition in patients with Alzheimer’s disease. Brain129(Pt 11), 2856–2866 (2006).
   PubMed Web of Science ®Google Scholar
• Rinne J, Brooks D, Rossor M et al.11C-PIB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer’s disease treated with bapineuzumab: a Phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol.9, 363–372 (2010).
   PubMed Web of Science ®Google Scholar
• Clark CM, Schneider JA, Bedell BJ et al. AV45-A07 Study Group. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA305(3), 275–283 (2011).
   PubMed Web of Science ®Google Scholar
• Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging32(4), 486–510 (2005).
   PubMed Web of Science ®Google Scholar
• Shin J, Lee S, Kim SJ, Kim SH, Cho S, Kim YB. Voxel-based analysis of Alzheimer’s disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG. Neuroimage52(2), 488–496 (2010).
   PubMed Web of Science ®Google Scholar
• Ishii K, Kanda T, Uemura T et al. Computer-assisted diagnostic system for neurodegenerative dementia using brain SPECT and 3D-SSP. Eur. J. Nucl. Med. Mol. Imaging36(5), 831–840 (2009).
   PubMed Web of Science ®Google Scholar
• Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J. Nucl. Med.36(7), 1238–1248 (1995).
   PubMed Web of Science ®Google Scholar
• Zubal IG, Early M, Yuan O, Jennings D, Marek K, Seibyl JP. Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson’s disease patients. J. Nucl. Med.48(6), 857–864 (2007).
   PubMedGoogle Scholar